Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer

Human Pathology

Volumn 27, Issue 9, 1996, Pages 917-921

  Shurbaji, M Salah ^a   Kalbfleisch, John H ^b   Thurmond, T Scott ^b  

^a East Tennessee State University   (United States)

^b NONE

Author keywords

enzymes; fatty acid synthase; immunohistochemistry; prognosis; prostate; prostatic neoplasms

Indexed keywords

FATTY ACID SYNTHASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER;

EID: 0029829119     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90218-X     Document Type: Article

References (31)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8-30, 1995
2. Catalona WJ, Bigg SW: Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients. J Urol 143:538-544, 1990
3. Scardino PT, Weaver R, Hudson MA: Early detection of prostate cancer. HUM PATHOL 23:211-222, 1992
4. Pritchett TP, Moreno J, Warner NE, et al: Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 139:1214-1216, 1988
5. Kabalin JN, McNeal JE, Price HM, et al: Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: Incidence, histology and morphometric observations. J Urol 141:1091-1094, 1989
6. Monte JE, Wood DP, Pontes E, et al: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 63:381-385, 1989
7. Winfield HN, Reddy PK, Lange PH: Coexisting adenocarcinoma of prostate in patients undergoing cystoprostatectomy for bladder cancer. Urology 30:100-101, 1987
8. Morse RM, Resnick MI: Detection of clinically occult prostate cancer. Urol Clin North Am 17:567-574, 1990
9. Foster CS, Mostofi FK: Prostate cancer-quo vadis? HUM PATHOL 23:402-406, 1992
10. Foster CS, Mostofi FK: Prostate cancer: Present status. HUM PATHOL 23:209-210, 1992
11. Humphrey PA, Walther PJ: Adenocarcinoma of the prostate. II. Tissue prognosticators. Am J Clin Pathol 100:256-269, 1993
12. Kuhajda FP, Piantadosi S, Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321:636-641, 1989
13. Shurbaji MS, Pasternack GR, Kuhajda FP: Expression of Haptoglobin-related protein in primary and metastatic breast cancers: A longitudinal study of 48 fatal cancers. Am J Clin Pathol 96:238-242, 1991
14. Shurbaji MS, Kuhajda FP, Pasternack GR, et al: Expression of oncogenic antigen 519 (OA519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol 97:689-691, 1992
15. Kuhajda FP, Jenner K, Wood FD, et al: Fatty acid synthesis: A potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91:6379-6383, 1994
16. Carmichael MJ, Epstein JI, Partin AW: OA519 (fatty acid synthase) a novel prognostic marker for prostate cancer: Correlation with pathologic stage. Mod Pathol 7:71A, 1994 (abstr)
17. Klein LA: Prostate carcinoma. N Engl J Med 300:824-833, 1979
18. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology: The Prostate. Malvern, PA, Lea & Febiger, 1977, pp 171-197
19. Broedel SE, Lang J, TungJ, et al: Characterization of tumorderived fatty acid synthase: A novel therapeutic target. Proc Am Assoc Cancer Res 35:86, 1994
20. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. HUM PATHOL 26:106-109, 1995
21. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Stata Reference Manual (Release 3.1). College Station, TX, Stata Corporation, 1993
23. SAS User's Guide: Statistics (Version 5). Cary, NC, SAS Institute, 1985
24. Mettlin C, Murphy GP, Ray P, et al: American Cancer Society-National Prostate Cancer Detection Project: Results from multiple examinations using rectal ultrasound, digital rectal examination, and prostate specific antigen. Cancer 71:891-898, 1993
25. Deitch AD, White RWD: Flow cytometry as a predictive modality in prostate cancer. HUM PATHOL 23:352-359, 1992
26. Ruidera ER, Thurmond TS, Shurbaji MS: Prognostic significance of flow cytometry and OA-519 in prostate cancer. Am J Clin Pathol 100:319, 1993
27. Visakorpi T, Kallioniemi O, Heikkinen A, et al: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992
28. Weiss L, Hoffman GE, Schreiber R, et al: Fatty-acid biosynthesis in man, a pathway of minor importance: Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe-Seyler 367:905-912, 1986
29. Lapossata M: Fatty acids: Biochemistry to clinical significance. Am J Clin Pathol 104:172-179, 1995
30. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1091-1098, 1993
31. Daneshgari F, Crawford ED: Endocrine therapy of advanced carcinoma of the prostate. Cancer 71:1089-1097, 1993